27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Future research should address the question of whether performance-based functional measures, as well as simple queries regarding whether functional activities take longer than usual to complete, may improve the prediction of future cognitive decline and disease progression among those individuals in whom MCI represents impending dementia. 1 key finding →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The results were consistent for both nursing homes and data were aggregated. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Healthcare Effectiveness Data and Information Set provides the dominant quality measurement framework for Medicare Advantage and commercial health plans, yet HEDIS lacks validated geriatric-specific quality indicators, equitable measurement standards for diverse older adult populations, and governance controls calibrated to the high-stakes Star Ratings financial incentive context. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Respondents (N=69) identified access to resources as the most important unmet need for caregivers (53%). 5 key findings →
Participants: 69 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Anti-amyloid monoclonal antibodies (lecanemab and donanemab) represent the first disease-modifying therapies for early symptomatic Alzheimer's disease (AD)- Italy's National Health Service (SSN) must determine whether to include these therapies within Essential Levels of Care (LEA), requiring reimbursement across all regions. 5 key findings →
Participants: 42,000 Evidence: low
Full summary, score breakdown and related studies → Original source
Over the past two decades the collaborative care model within primary care has proved to be effective in improving care quality, efficiency, and outcomes for older adults suffering from dementia and depression. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Caregiving for a parent living with dementia (PLWD) shapes former caregivers’ personal health planning. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Beyond these practical challenges, caregivers often endure significant physical exhaustion and sleep deprivation from the unrelenting demands of caregiving, which can lead to chronic fatigue and deteriorating health (Liu et al., 2022; Mao et al., 2024). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our analysis revealed a diverse range of topics reflecting community members' varying needs and concerns of individuals affected by AD/ADRD. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The attributes of concepts of social frailty and social isolation overlap, including being alone and having limited or less social activities, engagements or interactions. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
For co-residing care partners, high (p = 0.001), increased (p = 0.001), and decreased (p = 0.001) fall frequency over 2 years was significantly associated with emotional difficulties. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Potentially inappropriate medication (PIM) use-defined as the use of high-risk medications that can increase the risk of adverse events such as physical, cognitive, and functional decline; delirium; hospitalizations; and mortality-remains a significant concern in older adults in the US.Numerous guidelines, including the American Geriatrics Society Beers Criteria 1 and the STOPP criteria, 2 define PIMs as medications for which the risk of adverse effects outweighs potential benefits or are inappropriate for specific populations or disease states, such dementia or kidney disease.PIM use may be particularly harmful in populations experiencing other health care disparities, as communities experiencing other consequences of health care inequity, including limited access to physicians or pharmacies, greater financial stress, and a higher comorbidity burden, may experience disproportionate effects from the adverse consequences of PIM use. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Sixty studies were identified. Mental and physical effects caused by caregivers' sleep deprivation have been observed. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Six core themes were identified through the synthesis of data from 17 studies. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study aimed to evaluate the impact of the policy to reduce the reimbursement fee for percutaneous endoscopic gastrostomy (PEG) on the number of PEG procedures performed among older adults with dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Marginal utility of financial resources when needing long-term care, and the related incentives for precautionary savings and insurance, may vary significantly by whether one receives care at home or in a nursing home. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The rise in the ageing population has resulted in increased incident rates of cognitive impairment and dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This report reviews evidence on disorders related to inadequate vitamin D repletion in older people. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The uptake of advance care planning (ACP) is particularly low among people with dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Patients diagnosed with AD still mostly benefit from four compounds to significantly improve cognition functions and overall health and help manage other symptoms or even prolong the symptom-free period. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In 2009, nearly 66 million Americans (three in 10 U.S. households) reported at least one person providing unpaid care as a family caregiver. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The identified deficits in the medical care of the target population and the approaches to solving them will be incorporated into the development of health policy recommendations in order to optimize the care situation of those affected in the long term. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Zusammenfassung Die Alzheimer Krankheit (AD) ist eine schwere und fortschreitende neurodegenerative Erkrankung des Gehirns, die bislang mit primär nur symptomatisch wirksamen medikamentösen und nicht-medikamentösen Therapieformen als Standardtherapie behandelt wird. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Despite an aging population and acknowledged importance of advance care planning (ACP) for persons living with cognitive impairment, few engage in ACP. 5 key findings →
Participants: 17 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Amyloid-targeting antibody therapies for Alzheimer's disease require substantial diagnostic infrastructure including amyloid PET imaging, repeated MRI monitoring, and specialized clinical evaluation. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →